It is suggested that miR-183 may have a crucial important impact on the development of NSCLC, and the serum miR-183 level before treatment is related to the therapeutic effect of EGFR-TKI in advanced NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.